Skip to content
2000
Volume 7, Issue 1
  • ISSN: 1574-8863
  • E-ISSN: 2212-3911

Abstract

Clozapine, an atypical antipsychotic, is a dibenzodiazepine derivative and its therapeutic effects are probably mediated by dopaminergic and serotonergic activity. In accordance to several studies, it appears to be the most effective antipsychotic drug for treatment-resistant schizophrenia. Moreover, clozapine appears to be particularly beneficial in patients with schizophrenia who are suicidal and in those with comorbid substance use disorder. However, despite its efficacy, the general use of clozapine in clinical practice is somewhat limited because of the risk of several serious adverse effects such as agranulocytosis and thromboembolism. Clozapine may be associated with fatal myocarditis and cardiomyopathy in physically healthy young adults. Consequently, the FDA and the drug's manufacturer have strengthened warnings to include that a potentially fatal myocarditis may occur when taking clozapine. In the present paper the literature on clozapine-related myocardis will be reviewed and practical advice will be given concerning the diagnosis and management of such potentially fatal adverse effect.

Loading

Article metrics loading...

/content/journals/cds/10.2174/157488612800492681
2012-02-01
2025-07-08
Loading full text...

Full text loading...

/content/journals/cds/10.2174/157488612800492681
Loading

  • Article Type:
    Research Article
Keyword(s): cardiomyopathy schizophrenia; Clozapine; heart failure; myocarditis
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test